000			02348 a2200685 4500
005			20250516001409.0
264		0	_c20110408
008			201104s 0 0 eng d
022			_a2567-689X
024	7		_a10.1160/TH10-04-0247 _2doi
040			_aNLM _beng _cNLM
100	1		_aBecker, Richard C
245	0	0	_aEffect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. _h[electronic resource]
260			_bThrombosis and haemostasis _cNov 2010
300			_a976-83 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
650	0	4	_aAcute Coronary Syndrome _xblood
650	0	4	_aAdministration, Oral
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aBiomarkers _xblood
650	0	4	_aBlood Coagulation _xdrug effects
650	0	4	_aChi-Square Distribution
650	0	4	_aChromatography, Liquid
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDouble-Blind Method
650	0	4	_aDown-Regulation
650	0	4	_aEnzyme-Linked Immunosorbent Assay
650	0	4	_aFactor Xa _xmetabolism
650	0	4	_aFactor Xa Inhibitors
650	0	4	_aFemale
650	0	4	_aFibrin Fibrinogen Degradation Products _xmetabolism
650	0	4	_aFibrinolytic Agents _xadministration & dosage
650	0	4	_aHumans
650	0	4	_aInternational Normalized Ratio
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aOdds Ratio
650	0	4	_aPartial Thromboplastin Time
650	0	4	_aPeptide Fragments _xblood
650	0	4	_aPlacebo Effect
650	0	4	_aProthrombin
650	0	4	_aPyrazoles _xadministration & dosage
650	0	4	_aPyridones _xadministration & dosage
650	0	4	_aTandem Mass Spectrometry
650	0	4	_aThrombin _xmetabolism
650	0	4	_aTime Factors
650	0	4	_aTreatment Outcome
700	1		_aAlexander, John H
700	1		_aNewby, L Kristin
700	1		_aYang, Hongqiu
700	1		_aBarrett, Yuchen
700	1		_aMohan, Puneet
700	1		_aWang, Jessie
700	1		_aHarrington, Robert A
700	1		_aWallentin, Lars C
773	0		_tThrombosis and haemostasis _gvol. 104 _gno. 5 _gp. 976-83
856	4	0	_uhttps://doi.org/10.1160/TH10-04-0247 _zAvailable from publisher's website
999			_c20139564 _d20139564